The deletion of Ezh2 resulted in an MDS/MPN-like disease with myeloproliferative features such as the enhanced repopulating capacity of HSCs and extramedullary hematopoiesis in the spleen, and myelodysplastic features such as anemia accompanied by enhanced apoptosis in erythroblasts and dysplasia in myeloid cells. This evidence concerns the gene EZH2 and myeloproliferative neoplasm.